Adverse events to nontargeted and targeted chemotherapeutic agents: Emphasis on hypersensitivity responses

Immunology and Allergy Clinics of North America

Volumn 34, Issue 3, 2014, Pages 565-596

  Baldo, Brian A ^a,b   Pagani, Mauro ^c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CARLO POMA HOSPITAL   (Italy)

Author keywords

Adverse events to cancer drugs; Cancer drug hypersensitivities; Chemotherapeutic drug hypersensitivities; Desensitization to cancer drugs; Diagnosis of chemotherapeutic drug hypersensitivities; Monoclonal antibody adverse events; Monoclonal antibody hypersensitivities; Side effects of chemotherapeutic drugs

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MONOCLONAL ANTIBODY; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL PROTOCOL; CYTOPENIA; DESENSITIZATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SKIN REACTION; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOPATHOGENESIS; LUNG DISEASE; MALIGNANT NEOPLASTIC DISEASE; PAPULOPUSTULAR RASH; PARONYCHIA; PATHOGENESIS; PIGMENT DISORDER; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREMEDICATION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SERUM SICKNESS; SKIN FISSURE; SKIN TEST; VASCULITIS; XEROSIS; CLASSIFICATION;

ANTINEOPLASTIC AGENTS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; PREMEDICATION; RISK FACTORS;

EID: 84904046711     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2014.04.003     Document Type: Review

References (124)

1. Weiss R.B., Baker J.R. Hypersensitivity reaction from antineoplastic agents. Cancer Metastasis Rev 1987, 6(3):413-432.
2. Pagani M. The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am 2010, 94(4):835-852.
3. Baldo B.A., Pham N.H. Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer Metastasis Rev 2013, 32:723-761.
4. Ardavanis A., Tryfonopoulos D., Yiotis I., et al. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs 2004, 15(6):581-585.
5. National Cancer Institute NCI drug dictionary. Available at:. Accessed September 30, 2013. http://www.cancer.gov/drugdictionary.
6. Baldo B.A., Pham N.H. Ch. 11 Biologics; Ch. 13 Drugs used for chemotherapy. Drug allergy: clinical aspects, diagnosis, mechanisms, structure-activity relationships 2013, 369-385. Springer, New York, 399-418.
7. Baldo B.A. Adverse events to monoclonal antibodies used for cancer therapy. Focus on hypersensitivity responses. Oncoimmunology 2013, 2(10):e26333. 10.4161/onci.26333.
8. Syrigou E., Syrigos K., Saif M.W. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 2008, 8:56-62.
9. Zanotti K.M., Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 2001, 24:767-779.
10. Shepherd G.M. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003, 24:253-262.
11. Gadducci A., Tana R., Teti G., et al. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008, 18:615-620.
12. Weiss R.B. Hypersensitivity reactions. Semin Oncol 1992, 19:458-477.
13. Grosen E., Siitari E., Larrison E., et al. Paclitaxel hypersensitivity reactions related to bee-sting allergy. Lancet 2000, 355:288-289.
14. Markman M., Zanotti K., Kulp B., et al. Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol 2003, 89:514-516.
15. Sendo T., Sakai N., Itoh Y., et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol 2005, 56:91-96.
16. Schwartz J.R., Bandera C., Bradley A., et al. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. Gynecol Oncol 2007, 105:81-83.
17. Mori Y., Nishimura T., Kitano T., et al. Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Oncology 2010, 79:136-143.
18. Joly F., Ray-Coquard I., Fabbro M., et al. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 2011, 122(2):226-232.
19. Syrigou E., Dannos I., Kotteas E., et al. Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 2011, 156(3):320-324.
20. Piovano E., Pivetta E., Modaffari P., et al. Asearch for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms. Gynecol Obstet Invest 2012, 74(1):21-27.
21. Lee C., Gianos M., Klausermeyer W.B. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009, 102:179-187.
22. Demoly P., Bousquet J. Drug allergy diagnosis work up. Allergy 2002, 57(Suppl 72):37-40.
23. Wang H., Diepgen T.L. Is atopy a protective or a risk for cancer? A review of epidemiological studies. Allergy 2005, 60:1098-1111.
24. Herrero T., Tomero P., Infante S., et al. Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. JInvestig Allergol Clin Immunol 2006, 16:327-330.
25. Leguy-Seguin V., Jolimoy G., Coudert B., et al. Diagnosis and predictive value of skin testing in platinum salts hypersensitivity. JAllergy Clin Immunol 2007, 119:726-730.
26. Pagani M., Bonadonna P., Senna G.E., et al. Standardization of skin test for diagnosis and prevention of hypersensitivity reactions to oxaliplatin. Int Arch Allergy Immunol 2008, 145:54-57.
27. Castells M.C., Tennant N.M., Sloane D.E., et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. JAllergy Clin Immunol 2008, 122(3):574-580.
28. Garufi C., Cristaudo A., Vanni B., et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 2003, 14:497-502.
29. Meyer L., Zuberbier T., Worm M., et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. JClin Oncol 2002, 20:1146-1147.
30. Goldberg A., Altaras M.M., Mekori Y.A., et al. Anaphylaxis to cisplatin: diagnosis and value of pretreatment in prevention of recurrent allergic reactions. Ann Allergy 1994, 73:271-272.
31. Lee C.W., Matulonis U.A., Castells M.C. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 55 patients for 255 courses. Gynecol Oncol 2005, 99(2):393-399.
32. Madrigal-Burgaleta R., Berges-Gimeno M.P., Angel-Pereira D., et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 2013, 68(7):853-861.
33. Pagani M., Venemalm L., Bonadonna P., et al. An experimental biological test to diagnose hypersensitivity reactions to carboplatin: new horizons for an old problem. Jpn J Clin Oncol 2012, 42:347-350.
34. Weiss R.B., Donehower R.C., Wiernik P.H., et al. Hypersensitivity reactions from. Taxol J Clin Oncol 1990, 8(7):1263-1268.
35. Popescu N.A., Sheehan M.G., Kouides P.A., et al. Allergic reactions to cyclophosphamide: delayed clinical expression associated with positive immediate skin tests to drug metabolites in five patients. JAllergy Clin Immunol 1996, 97:26-33.
36. Rosas-Vargas M.A., Casas-Becerra B., Velázquez-Armenta Y., et al. Cyclophosphamide hypersensitivity in a leukemic child. Ther Drug Monit 2005, 27:263-264.
37. Khan A., Hill J.M. Atopic hypersensitivity to L-asparaginase: resistance to immunosuppression. Int Arch Allergy Appl Immunol 1971, 40:463-469.
38. Giguere J.K., Douglas D.M., Lupton G.P., et al. Procarbazine hypersensitivity manifested as a fixed drug eruption. Med Pediatr Oncol 1988, 16:378-380.
39. de Souza P., Friedlander M., Wilde C., et al. Hypersensitivity reactions to etoposide. Am J Clin Oncol 1994, 17:387-389.
40. Brockow K., Garvey L.H., Aberer W., et al. Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interested Group position paper. Allergy 2013, 68:702-712.
41. National Cancer Institute. Common Terminology Criteria for Adverse Events v4.03 (CTCAE). 2009. Available at:. Accessed October 30, 2013. http://ctep.cancer.gov.
42. Dizon D.S., Sabbatini P.J., Aghahanian C. Analysis of patients with epithelial ovarian cancer of fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002, 84:378-382.
43. Elligers K.T., Davies M., Sanchis D., et al. Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?. JOP 2008, 9:197-202.
44. Enrique E., Malek T., Castello J.V., et al. Usefulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin. Ann Allergy Asthma Immunol 2008, 100:86.
45. Lokich J., Anderson N. Paclitaxel hypersensitivity reactions: a role for docetaxel substitution. Ann Oncol 1998, 9:573-574.
46. Moon C., Verschraegen C.F., Bevers M., et al. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 2000, 11:565-568.
47. Dizon D.S., Schwartz J., Rojan A., et al. Cross-sensitivity between paclitaxel and docetaxel in a women's cancer program. Gynecol Oncol 2006, 100:149-151.
48. Sanchez-Munoz A., Jimenez B., Garcia-Tapiador A., et al. Cross-sensitivity between taxanes in patients with breast cancer. Clin Transl Oncol 2011, 13:904-906.
49. Hak L.J., Relling M.V., Cheng C., et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 2004, 18:1072-1077.
50. Silverman L., Gelber R.D., Dalton V.K., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber consortium protocol 91-01. Blood 2001, 97:1211-1218.
51. Soyer O.U., Aytac S., Tuncer A., et al. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia. JAllergy Clin Immunol 2009, 123:895-898.
52. Kintzel P.E. Prophylaxis for paclitaxel hypersensitivity reactions. Ann Pharmacother 2001, 35:1114-1117.
53. Berger M.J., Dunlea L.J., Rettig A.E., et al. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing previous infusion hypersensitivity reaction. Support Care Cancer 2012, 20:1991-1997.
54. Olson J.K., Sood A.K., Sorosky J.I., et al. Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynecol Oncol 1998, 68:25-28.
55. Markman M., Kennedy A., Webster K., et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynaecologic oncology program of the Cleveland Clinic Cancer Center. JClin Oncol 2000, 18:102-105.
56. Stock W., Douer D., De Angelo D.J., et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma 2011, 52:2237-2253.
57. Brandi G., Pantaleo M.A., Galli C., et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003, 89:477-481.
58. Maindrault-Goebel F., Andrè T., Turnigard C., et al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005, 41:2262-2267.
59. Polyzos A., Tsavaris N., Kosmos C., et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. Oncology 2001, 61:129-133.
60. Markman M., Zanotti K., Peterson G., et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. JClin Oncol 2003, 21:4611-4614.
61. Pagani M., Bonadonna P. Skin test protocol for the prevention of hypersensitivity reactions to oxaliplatin. Anticancer Res 2014, 34:537-540.
62. Limsuwan T., Castells M.C. Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity. Expert Opin Drug Saf 2010, 9(1):39-53.
63. Scherer K., Brockow K., Aberer W., et al. Desensitization in delayed drug hypersensitivity reactions: an EAACI position paper of the Drug Allergy Interesting Group. Allergy 2013, 68:844-852.
64. Cernadas J.R., Brockow K., Romano A. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010, 65:1357-1366.
65. Patil S.U., Long A.A., Ling M., et al. Aprotocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. JAllergy Clin Immunol 2012, 129:443-447.
66. Levitski A., Klein S. Signal transduction therapy of cancer. Mol Aspects Med 2010, 31(4):287-329.
67. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat Rev Cancer 2012, 12:278-287.
68. Turturro F. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid- derived disorders. Expert Rev Anticancer Ther 2007, 7(1):11-17.
69. Lockhart A.C., Rothenberg M.L., Dupont J., et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. JClin Oncol 2010, 28(2):207-214.
70. Kisselev A.F., van der Linden W.A., Overkleeft H.S. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 2012, 19(1):99-115.
71. Moreau P., Richardson P.G., Cavo M., et al. Proteasome inhibitors in multiple myeloma: ten years later. Blood 2012, 120:947-959.
72. Ward H.W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1973, 1(5844):13-14.
73. Gleevec. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 1, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021588s035lbl.pdf.
74. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. NEngl J Med 2002, 346(9):645-652.
75. Tarceva. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 1, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf.
76. Afinitor. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 1, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf.
77. Zolinza. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 1, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf.
78. Vesanoid. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 1, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20438s004lbl.pdf.
79. Targretin. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 1, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021055s006lbl.pdf.
80. Velcade. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 1, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021602s027lbl.pdf.
81. Arimidex. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 1, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020541s026lbl.pdf.
82. Zoladex. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 1, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019726s054,020578s032lbl.pdf.
83. Nolvadex. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 1, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/17970s053lbl.pdf.
84. Casodex. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 1, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020498s019s021lbl.pdf.
85. Folotyn. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 1, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022468s003s004s005lbl.pdf.
86. Ontak. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103767s5094lbl.pdf.
87. Zaltrap. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125418s000lbl.pdf.
88. Thurston D.E. Chemistry and pharmacology of anticancer drugs 2007, 95-150. CRC Press, Boca Raton (FL).
89. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2009, 112:4808-4817.
90. European Medicines Agency evaluation of medicines for human use. Assessment report for Removab. Proc. no. EMEA/H/C/000972, 2009. Available at:. Accessed October 2, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000972/WC500051808.pdf.
91. Zevalin. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125019s0156.pdf.
92. Bexxar. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125011s102lbl.pdf.
93. Hansel T.T., Kropshofer H., Singer T., et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010, 9:325-338.
94. Rituxan. FDA: Full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf.
95. Arzerra. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125326lbl.pdf.
96. Adcetris. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125388s0005lbl.pdf.
97. Erbitux. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125084s168lbl.pdf.
98. Vectibix. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125147s080lbl.pdf.
99. Avastin. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125085s0238lbl.pdf.
100. Perjeta. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125409lbl.pdf.
101. Herceptin. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5256lbl.pdf.
102. Kadcyla. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf.
103. Campath-1H. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103948s5070lbl.pdf.
104. Xgeva. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125320s094lbl.pdf.
105. Yervoy. FDA: full prescribing information. Adverse reactions. Available at:. Accessed October 2, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf.
106. Dy G.K., Adjei A.A. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013, 63:249-279.
107. Degan A., Alter M., Schenck F., et al. The hand-foot-syndrome associated with medical tumor therapy - classification and management. JDtsch Dermatol Ges 2010, 8(9):652-661.
108. Criscitiello C., Metzger-Filho O., Saini K.S., et al. Targeted therapies in breast cancer: are heart and vessels also being targeted?. Breast Cancer Res 2012, 14:209.
109. Balagula Y., Lacouture M.E., Cotliar J.A. Dermatologic toxicities of targeted anticancer therapies. JSupport Oncol 2010, 8(4):149-161.
110. Polder K., Wang C., Duvic M., et al. Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma. Leuk Lymphoma 2005, 46(12):1807-1811.
111. Coombs R.R., Gell P.G. Classification of allergic reactions responsible for clinical hypersensitivity and disease. Clinical aspects of immunology 1975, 761-781. Blackwells, Oxford (United Kingdom). P.G. Gell, R.R. Coombs, P.J. Lachmann (Eds.).
112. Ansari Z., George M.K. Drug-induced immune-mediated thrombocytopenia secondary to sunitinib in a patient with metastatic renal cell carcinoma: a case report. JMed Case Rep 2013, 7:54.
113. Barak A.F., Bonstein L., Lauterbach R., et al. Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?. Hematol Rep 2011, 3:e29. 95-6.
114. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007, 12:864-872.
115. Arnold D.M., Santoso S., Greinacher A., on behalf of the Platelet Immunology Scientific Subcommittee of the ISTH Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia. JThromb Haemost 2012, 10(4):695-697.
116. Salama A., Schütz B., Kiefel V., et al. Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol 1989, 72(2):127-132.
117. Giavina-Bianchi P., Caiado J., Picard M., et al. Rapid desensitization to chemotherapy and monoclonal antibodies is effective and safe. Allergy 2013, 68:1482-1483.
118. Bar-Sela G., Kedem E., Hadad S., et al. Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor. Jpn J Clin Oncol 2010, 40(2):163-165.
119. Chou V., McClelland S., Resnick D.J., et al. Successful desensitization of an adult with type I hypersensitivity to imatinib. Internet J Asthma Allergy Immunol 2005, 4(2). 10.5580/1a78.
120. Nelson R.P., Cornetta K., Ward K.E., et al. Desensitization to imatinib in patients with leukemia. Ann Allergy Asthma Immunol 2006, 97(2):216-222.
121. Jerath M.R., Kwan M., Kannarkar M., et al. Adesensitization protocol for the mAb cetuximab. JAllergy Clin Immunol 2009, 123:260-262.
122. Hong D.I., Bankova L., Cahill K.N., et al. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol 2012, 8(1):43-52.
123. Brennan P.J., Rodriguez-Bouza T., Hsu F.I., et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. JAllergy Clin Immunol 2009, 124:1259-1266.
124. Pàez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(3):220-231.